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Insulin-like growth factor-I (IGF-I) stimulation of basal
keratinocytes is an essential component of normal
epidermal homeostasis. In addition to the IGF receptor,
basal keratinocytes synthesize insulin-like growth factor
binding protein-3 (IGFBP-3). The HaCaT keratinocyte
cell line, which has many characteristics of basal
keratinocytes, synthesizes IGFBP-3 that in vitro reduces
its IGF-I responsiveness. IGFBP-3 has attracted interest
as a potential growth arrest protein, both via its ability to
modulate IGF-I responsiveness, and more controversially
via IGF-I-independent mechanisms. Intracellular modes
of action have been proposed, and a nuclear localization
consensus sequence has previously been identified within
IGFBP-3. Using immunocytochemistry with a bio-
tinylated antibody specific for IGFBP-3, we investigated
the intracellular localization of IGFBP-3 in subconfluent
Insulin-like growth factor binding protein-3 (IGFBP-3) is asecreted protein with mostly insulin-like growth factor I(IGF-I)-antagonistic effects and is synthesized by many celltypes (Jones and Clemmons, 1995). Human epidermal keratino-cytes synthesize IGFBP-3 that blunts the ability of exogenous
IGF-I to stimulate mitosis, at least in vitro (Wraight et al, 1994). In the
epidermis, IGFBP-3 is the predominant IGFBP species (Batch et al,
1994) and is only synthesized by basal keratinocytes (Wraight et al,
1997), where its expression is highly regulated. In the psoriatic lesion,
the pattern of IGFBP-3 expression inversely correlates with keratinocyte
growth rates (Wraight et al, 1997). Consistent with this, the keratinocyte
mitogen, epidermal growth factor, is a potent inhibitor of IGFBP-3
synthesis in keratinocytes (Wraight and Werther, 1995).
Many previous studies on IGFBP have focused on their actions at
the cell surface (Jones and Clemmons, 1995). The presence of a nuclear
localization consensus sequence in its primary structure (Radulescu,
1994) suggested that IGFBP-3 may have intranuclear actions, for
example, in gene regulation. We therefore investigated whether
IGFBP-3 appears in the nucleus of human keratinocytes and therefore
whether the potential exists for intranuclear growth inhibitory signaling
via IGFBP-3 in human epidermis.
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monolayer cultures of HaCaT cells. Diffuse cellular stain-
ing was visible, potentially corresponding to cell surface
and nascent cytoplasmic IGFBP-3. Of particular interest
however, was the localization of staining over the nuclei
of a large proportion of cells that were undergoing cell
division. Antibody staining was specific for IGFBP-3
because addition of recombinant human IGFBP-3 to the
antibody prior to incubation with the cells inhibited
these staining patterns. Optical sections obtained using
a confocal laser scanning microscope showed that in
keratinocytes undergoing cell division, IGFBP-3 was
localized inside the nucleus. These results show that
intracellular IGFBP-3 localization is altered during the
cell cycle and suggest a possible nuclear role for IGFBP-
3 during cell division. Key words: cytokine/IGF-I/mitosis/
nucleus. J Invest Dermatol 111:239–242, 1998
MATERIALS AND METHODS
Reagents An affinity-purified, biotinylated goat anti-serum specific for human
IGFBP-3, and which specifically recognizes the 38–42 kDa IGFBP-3 protein
in western analysis (Bereket et al, 1995; Conover et al, 1995; Hasegawa et al,
1995), was generously provided by Dr. C.J. Strasburger (Ludwig-Maximilians-
Universita¨t, Munich, Germany). An affinity-purified rabbit anti-Ki67 antibody
was purchased from DAKO (Glostrup, Denmark). Trypsin, Dulbecco’s modified
Eagle’s medium, and fetal bovine serum were purchased from Trace Biosciences
(Clayton, Australia).
Cells The immortalized human keratinocyte cell line, HaCaT (Boukamp
et al, 1988), was kindly provided by Prof. N. Fusenig (German Cancer Research
Center, Heidelberg, Germany). Cells at passage numbers 43–45 were maintained
as monolayer cultures in 5% CO2 at 37°C in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum. At confluence, cells were
detached by incubating with 4 mM ethylenediamine tetraacetic acid followed
by 0.025% trypsin, 0.5 mM ethylenediamine tetraacetic acid, then seeded onto
autoclaved glass microscope slides. Cells were grown to 90% confluence, washed
in phosphate buffered saline (PBS), and fixed with 4% paraformaldehyde in
PBS for 20 min at room temperature. Fixed monolayers were permeabilized
and dehydrated through graded ethanol and then stored desiccated at 4°C.
Immunostaining Fixed cells on glass slides were boiled in a microwave
oven in 10 mM sodium citrate, pH 6.0, for 10 min then washed three times
in PBS at room temperature. All subsequent steps were performed at room
temperature. Slides were incubated in methanol containing 1% hydrogen
peroxide, then in PBS containing 1% bovine serum albumen, 20 µg sheep IgG
(Silenus, Hawthorn, Australia) per ml for 30 min each. Slides were then
incubated in PBS containing 0.1% bovine serum albumen and the biotinylated
anti-human IGFBP-3 (13 µg per ml) for 3 h. To test for immunospecificity,
the antibody was incubated with 15 µg recombinant human IGFBP-3 (Upstate
Biotechnology, NY) per ml at room temperature for 30 min before applying
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Figure 1. HaCaT keratinocyte nuclei stain positive for IGFBP-3 by
immunostaining. A subconfluent monolayer culture of HaCaT cells was fixed
in paraformaldehyde, permeabilized, and immunostained with an affinity
purified, biotinylated antibody specific for human IGFBP-3, counter-stained in
hematoxylin as described in Materials and Methods, and then viewed under light-
field microscopy. (a) IGFBP-3 positive nuclei are indicated by the brown
immunostaining. The nuclei of cells undergoing division are clearly positive
for IGFBP-3 staining (arrows). In nondividing cells, cellular (non-nuclear)
staining is visible. Scale bar, 40 µm. (b) Immunostaining is blocked by the
inclusion of 15 µg recombinant human IGFBP-3 per ml with the antibody
incubation, showing that the staining patterns were specifically due to the
presence of IGFBP-3. Scale bar, 50 µm. (c) Incubation with a biotinylated goat
IgG antibody as a negative control for the primary antibody showing the
specificity of the detection system for the presence of IGFBP-3. Scale bar, 50 µm.
to the cells. Additionally, the antibody was replaced with preimmune biotinylated
goat IgG (Jackson ImmunoResearch Laboratories, West Grove, PA). After
incubating slides in the primary antibody as above, the cells were processed
using a Vectastain ABC Elite avidin-biotin-peroxidase detection kit (Vector
Laboratories, Burlingame, CA) with 3,39-diaminobenzidine as the peroxidase
substrate (brown, Sigma, St. Louis, MO), and lightly counterstained with
hematoxylin.
Immunofluorescence Fixed cells were treated and incubated at 4°C over-
night with the biotinylated anti-IGFBP-3 antibody as described above, then
after washing the slides in PBS, the cells were incubated with fluorescein
isothiocyanate (FITC)-conjugated streptavidin (12 µg per ml) followed by anti-
streptavidin (5 µg per ml) and finally FITC-streptavidin again to amplify the
signal. Anti-streptavidin and FITC-streptavidin were from Vector Laboratories.
All incubations were for 30 min at room temperature, washing with PBS
between each incubation. Slides were mounted in Mowiol (Hoechst, Frankfurt,
Germany) containing 2.5% 1,4-diazobicyclo[2,2,2]-octane (DABCO) antifade
(Sigma) and viewed with a Leitz Diaplan fluorescence microscope.
Confocal microscopy Cells were immunostained as described above and
viewed on an Optiscan F900e fiber optic laser scanning confocal microscope
(Optiscan, Melbourne, Australia) with a 603 lens (numerical aperture 5 1.4)
and a 1300 nm diameter optical fiber (equivalent to a pin-hole size of 1300 nm),
producing a z-axis resolution of 1 µm.
RESULTS
Keratinocyte nuclei stain positive for IGFBP-3 during cell
division Analysis of HaCaT keratinocyte monolayers using an anti-
body specific for human IGFBP-3 showed that most cells had diffuse
cytoplasmic and/or surface IGFBP-3, indicated by the brown staining
(Fig 1a). Of particular interest, however, was the detection of a small
but significant proportion of dividing cells with intense brown staining
Figure 2. HaCaT keratinocyte nuclei stain positive for IGFBP-3 by
immunofluorescence. A subconfluent monolayer culture of HaCaT human
keratinocytes was fixed in paraformaldehyde, permeabilised, and incubated with
a biotinylated antibody specific for human IGFBP-3. Antibody localization
was detected with FITC-conjugated streptavidin followed by fluorescence
microscopy as described in Materials and Methods. (a) IGFBP-3 positive nuclei
are clearly visible in dividing keratinocytes. Some extranuclear fluorescence is
visible in cells not undergoing division. Scale bar, 10 µm. (b) Immunofluorescence
is blocked by the inclusion of 15 µg recombinant human IGFBP-3 per ml with
the antibody incubation showing that the immunofluorescence was specifically
due to the presence of IGFBP-3. Scale bar, 10 µm. (c) Incubation with a
biotinylated goat IgG as a negative control for the primary antibody. Scale bar,
10 µm. (d) Keratinocyte monolayer without the antibody detection system
showing negligible autofluorescence. Scale bar, 10 µm.
in the region of the cell nucleus (Fig 1a). This staining pattern was
specific for IGFBP-3, as shown by the lack of both nuclear and non-
nuclear staining when antibody binding is blocked by the addition of
recombinant IGFBP-3 (Fig 1b). Figure 1(c) is a negative control
showing no staining when a biotinylated preimmune goat IgG is used
instead of the IGFBP-3-specific antibody.
The localization of IGFBP-3 in the keratinocytes was also analyzed
using immunofluorescence to determine if a fluorescein-conjugated
antibody detection system produced the same staining pattern as that
shown in Fig 1. As shown in Fig 2(a), nuclear fluorescence was clearly
visible in dividing cells. Other nondividing cells were visible that
exhibited diffuse extranuclear fluorescence only (Fig 2a). Figure 2(b)–
(d) are negative control monolayers that also contained several dividing
keratinocytes per field, showing abrogation of IGFBP-3 immuno-
staining with (i) the coaddition of recombinant IGFBP-3 (Fig 2b), (ii)
incubation with biotinylated preimmune goat IgG instead of specific
antibody (Fig 2c), and (iii) an absence of antibodies or FITC-conjugated
streptavidin (to exclude the possibility of autofluorescence) (Fig 2d).
IGFBP-3 is inside the nucleus during keratinocyte division To
ensure that the apparent nuclear staining with the IGFBP-3 antibody
was not due to IGFBP-3 present in perinuclear structures such as, for
example, Golgi apparatus or secretory vesicles, laser scanning confocal
microscopy was performed on keratinocyte monolayers that had been
prepared as described above for immunofluorescence. This technique
has the ability to differentiate between proteins located within or
peripheral to the nucleus by taking thin optical sections through
subcellular structures. Optical sections (1 µm thick) through the nuclei
of dividing keratinocytes consistently demonstrated the presence of
IGFBP-3 throughout the nucleus (Fig 3).
Monolayers of HaCaT keratinocytes contain a high proportion
of dividing cells To determine the proportion of actively dividing
keratinocytes present in the HaCaT monolayer cultures, the monolayers
were immunostained with an antibody specific for the cell cycle
associated nuclear antigen, Ki67. Ki67 is expressed most abundantly
during M phase but is also detectable in G1, S, and G2. Counting of
several representative fields showed that monolayers contained µ10%
Ki67-positive cells (Fig 4). Monolayers matching those in Figs 1–3
thus contain a significant proportion of actively dividing cells.
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Figure 3. IGFBP-3 detected inside the nuclei of dividing human
keratinocytes by scanning laser confocal microscopy. Sub-confluent
monolayers of HaCaT human keratinocytes were fixed in paraformaldehyde,
permeabilized, and incubated with a biotinylated antibody specific for human
IGFBP-3. After incubation with FITC-conjugated streptavidin, cells were
analyzed by scanning laser confocal microscopy. The figure shows IGFBP-3
immunofluorescence in a 1 µm thick optical section through dividing
keratinocytes. Scale bar, 10 µm.
Figure 4. Sub-confluent keratinocyte monolayers contain a high
proportion of dividing cells as detected by Ki67 immunostaining.
A subconfluent monolayer of HaCaT human keratinocytes was fixed in
paraformaldehyde, permeabilized, and incubated with a polyclonal rabbit
antibody specific for Ki67. (a) Actively dividing cells in the monolayer are
indicated by the presence of brown immunostained nuclei. Scale bar, 50 µm.
(b) A negative control (rabbit preimmune serum) for the Ki67 antibody shows
no staining. Scale bar, 50 µm.
DISCUSSION
IGFBP-3 has been studied extensively as an IGF-I carrier in serum
and as a modulator of IGF-I action at the cell surface of target tissues
(Jones and Clemmons, 1995). A potential role for IGFBP-3 in cell
growth arrest has been supported by recent data that the IGFBP-3
promoter contains an active response element for the tumor suppressor
protein, p53 (Buckbinder et al, 1995), that expression of the IGFBP-3
gene caused premature growth arrest in transfected mouse fibroblasts
(Cohen et al, 1993), and that IGFBP-3 appears to mediate the growth
inhibitory effects of transforming growth factor-β and retinoic acid in
a human breast cancer cell line (Oh et al, 1995; Gucev et al, 1996).
Other studies have identified growth inhibitory mechanisms of IGFBP-3
(Valentinis et al, 1995; Rajah et al, 1997) or of proteolytic fragments
derived from IGFBP-3 (Lalou et al, 1996) that appear to be independent
of IGF receptor signaling. Data consistent with the existence of a cell
surface receptor for IGFBP-3 (Oh et al, 1993) also suggest that IGFBP-3
growth inhibitory mechanisms may go beyond a role in inhibiting the
interaction of IGF-I and its receptor at the cell surface.
The identification of a nuclear localization consensus sequence in
IGFBP-3 (Radulescu, 1994) originally highlighted the possibility that
IGFBP-3 has an intracellular function, potentially in gene regulation.
Our demonstration of intranuclear IGFBP-3 in keratinocytes suggests
that these as yet unknown functions may be important in the regulation
of epidermal growth. If nuclear IGFBP-3 has a biologic function, the
question of whether nuclear IGFBP-3 works via an IGF-dependent
or IGF-independent mechanism remains. During the preparation of
this manuscript, two reports on nuclear IGFBP-3 in other cell types
were published, one of which reported the detection of transport of
IGF-I/IGFBP-3 complexes to the nucleus of opossum kidney cells (Li
et al, 1997). Consistent with our own data, nuclear transport only
occurred in actively dividing cells. In the other report, nuclear IGFBP-3
was detected in a lung cancer cell line (Jaques et al, 1997). A feature
of this study is that the thin optical sectioning technique of confocal
microscopy effectively distinguishes between intranuclear IGFBP-3
and IGFBP-3 that may be merely associated with the nucleus, nuclear
envelope, or adherent perinuclear organelles.
There are two possibilities for the cellular origin of nuclear IGFBP-3
in keratinocytes: (i) a certain proportion of nascent IGFBP-3 is diverted
from its secretory pathway to a nuclear transport pathway at cell
division, or (ii) extracellular IGFBP-3 is internalised and transported
to the nucleus at cell division. It remains to be seen at which stage of
the cell cycle this translocation occurs. Fibroblast growth factor-1,
another secreted protein with a nuclear localization signal (Imamura
et al, 1990), is known to translocate to the nucleus during late G1
phase of the cell cycle (Imamura et al, 1994). It is interesting to observe
that the immunostaining pattern of nuclear IGFBP-3 differs slightly
from that of Ki67. This could suggest either that Ki67 and IGFBP-3
appear in the nucleus at different stages of the cell cycle, or that they
have different intranuclear distributions. Further studies are required
to pinpoint the exact phase at which nuclear IGFBP-3 appears in
keratinocytes.
Further studies will also be required to investigate the occurrence
of nuclear IGFBP-3 in the epidermis in vivo. Whereas our inspections
of skin sections have not so far shown nuclear IGFBP-3 localization
in the basal cells of the human epidermis, which is the in vivo localization
of IGFBP-3 in the epidermis (Batch et al, 1994; Wraight et al, 1997),
this is perhaps not surprising, considering the small proportion of basal
keratinocytes undergoing cell division in vivo. Ki67 staining, which
identifies any cells not in G0, stains only about one in 50 cells of the
basal epidermis in our studies (data not shown). This correlates with
the published observations of Hodak et al (1996). Of these cells, which
are in any of G1, S, G2, or M phases, only a small proportion will be
in M, and then only a small proportion of these will be undergoing
cytokinesis, the stage at which IGFBP-3 appears to localize in the
nucleus in keratinocytes.
The paracrine interaction of IGF-I from the dermis (Minuto et al,
1991; Tavakkol et al, 1992) with the IGF receptor in basal keratinocytes
(Hodak et al, 1996) is known to be essential for the normal development
of the differentiated epidermal layers (Liu et al, 1993). Our previous
studies have shown that IGFBP-3 expression in the basal layer is likely
to play a key role in this interaction (Wraight et al, 1994, 1997). This
study indicates that IGFBP-3 in basal keratinocytes could have far
more complex mechanisms of action than previously envisaged in the
control of epidermal growth.
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